Hong Simon J, Katz Seymour
Inflammatory Bowel Disease Center at New York University Langone Health, Division of Gastroenterology and Hepatology, 305 East 33rd Street, New York, NY 10016-4576, USA.
Inflammatory Bowel Disease Center at New York University Langone Health, Division of Gastroenterology and Hepatology, New York, NY, USA.
Therap Adv Gastroenterol. 2021 Jul 3;14:17562848211023399. doi: 10.1177/17562848211023399. eCollection 2021.
The incidence and prevalence of inflammatory bowel disease (IBD) is rising in the elderly population. Compared with patients with onset during their younger years, patients with elderly onset IBD have a distinct clinical presentation, disease phenotype, and natural history. Genetics contribute less to pathogenesis of disease, whereas biological changes associated with aging including immunosenescence, dysbiosis, and frailty have a greater impact on disease outcomes. With the advent of an increasingly wider array of biologic and small-molecule therapeutic options, data regarding efficacy and safety of these agents in elderly IBD patients specifically are paramount, given the unique characteristics of this population.
炎症性肠病（IBD）在老年人群中的发病率和患病率正在上升。与年轻时发病的患者相比，老年发病的IBD患者具有独特的临床表现、疾病表型和自然病史。遗传因素在疾病发病机制中的作用较小，而与衰老相关的生物学变化，包括免疫衰老、肠道菌群失调和身体虚弱，对疾病结局的影响更大。随着生物制剂和小分子治疗选择的日益增多，鉴于该人群的独特特征，有关这些药物在老年IBD患者中的疗效和安全性的数据至关重要。
